GSK Receives Positive Vote from FDA on Votrient for Soft Tissue Sarcoma

Share this content:

(Chemotherapy Advisor) – GlaxoSmithKline announced on March 20 that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration voted 11 to 2 that there was sufficient clinical evidence and a favorable benefit-risk assessment for use of Votrient (pazopanib) in treating patients with advanced soft-tissue sarcoma who have received prior chemotherapy. Gastrointestinal stromal tumors (GIST) and adipocytic sarcomas were not included in this Phase 3 trial.

The ODAC reviewed data from one Phase 2 and one Phase 3 trial. ODAC is charged with providing the FDA with independent advice and recommendations, but approval of the drug ultimately falls to the FDA. Votrient is currently indicated for the treatment of renal cell carcinoma in the United States, United Kingdom, and European Union, but not approved or licensed in the United States or European Union for the treatment of advanced soft-tissue sarcoma.  

"Treatment options for patients with advanced soft-tissue sarcoma are limited; we are therefore pleased that the Committee took a favorable view of the clinical data for Votrient," said Rafael Amado, Senior Vice President, GlaxoSmithKline Oncology. "We look forward to continuing the regulatory process."

Press Release

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs